Video

Dr. Moul on Impact of Obesity in Active Surveillance

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

The guidelines for following up on active surveillance, such as how often a biopsy should be performed and where molecular markers may fit in, can be challenging, Moul explains. Previous data suggest that, following a radical prostatectomy, obese men have a higher risk of disease recurrence. This study, led by Moul, examined the impact of obesity on men undergoing active surveillance for prostate cancer.

Researchers found that obese men may have a higher risk of disease recurrence on active surveillance. Additionally, their disease could be of a higher grade when analyzed on a repeat biopsy.

Though this is preliminary data, Moul suggests that obese men may not be as ideal candidates for active surveillance as men with a normal body mass index.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
Neeta Somaiah, MD
Omid Hamid, MD
Marlana M. Orloff, MD